PharmaBoardroom

What Three Pharma Leaders Want to Share About Switzerland

PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their…

China: 2020’s Biggest Biotech IPO in Profile

RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling…

Jan Tangermann – Country Head, Sandoz Switzerland

Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable…

Aducanumab edges closer to Potential Approval: Next up, the…

In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…

Emerging Markets: How COVID-19 is Throwing New Light on the Role…

Dr Ann Aerts, head of the Novartis Foundation, highlights how the COVID-19 crisis has thrust artificial intelligence in healthcare into the limelight,…

Four Cell & Gene Companies to Know in China

While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese…

Stephen Farr – President & CEO, Zogenix

Zogenix’s Dr Stephen Farr shares his remarkable career journey from academia to industry, the company’s transition from pain therapeutics into…

Cell & Gene Therapy: Command? Consent? Collaborate!

Novartis Oncology’s Emanuele Ostuni (lead author) and Karin Blumer draw on their experience commercialising CAR-T therapies to make the case for the…

Henrik Asmussen – General Manager, Amgen Switzerland

In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges,…

Moving the Needle on Gender Diversity in Swiss Pharma Leadership

While Switzerland has Europe's second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and…

Edigene CEO on Gene Editing Biotech’s Ambitious Expansion Plans

Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and…

LatAm: Big Indian Investment; Argentina’s COVID-19 Woes;…

The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing…

Tagged with GE